Insights Advancing the Future of Pharmaceuticals

Disease-area strategy — Disease-area Strategy

Find out which indications offer the best commercial opportunities and how to prioritize them

Business Development & Early R&D

Assess an asset's commercial potential, whether you're evaluating an in-licensing opportunity or shaping a target product profile

Late-stage Development

Dive into our patient-share forecasting, patient-flow modeling, and market access tools

How This All Works — Our Unmet need framework

Discover the framework at the heart of our analysis and how we use it to predict patient share

Recent Insights

Our Take Blog

Lifyorli-Figure (3).jpg

Apr 7, 2026

Oncology

Lifyorli Approved in Platinum-Resistant Ovarian Cancer Thanks to a 35% Reduction in Mortality

Apr 7, 2026

Oncology

Read More →

Apr 7, 2026

Oncology

oveporexton Figure.jpg

Mar 31, 2026

Chronic Diseases

Oveporexton Could be a Game-changer for Narcolepsy Type 1

Mar 31, 2026

Chronic Diseases

Read More →

Mar 31, 2026

Chronic Diseases

The Problem with Primary Market Research

Mar 4, 2026

R&D Insights

The Problem with Primary Market Research

Mar 4, 2026

R&D Insights

Read More →

Mar 4, 2026

R&D Insights

Feb 17, 2026

Chronic Diseases

Gene Therapies for Sickle Cell Disease: Expensive but Worth It

Feb 17, 2026

Chronic Diseases

Read More →

Feb 17, 2026

Chronic Diseases

Feb 13, 2026

Oncology

Keytruda Grabs its 42nd Approval in PD-L1+ PROC

Feb 13, 2026

Oncology

Read More →

Feb 13, 2026

Oncology

Plan for the Best, Prepare for the Worst - Handling Uncertainty in R&D

Feb 10, 2026

R&D Insights

Plan for the Best, Prepare for the Worst - Handling Uncertainty in R&D

Feb 10, 2026

R&D Insights

Read More →

Feb 10, 2026

R&D Insights

Want to read more? Click below